代謝性アシドーシスの治療におけるVeverimerの有効性と安全性を評価する研究
慢性腎臓病と代謝性アシドーシスを有する成人におけるVeverimerの有効性と安全性を評価する第3相ランダム化二重盲検試験（REVIVE試験）
The purpose of this study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前：Ayla Rasmussen
- 電話番号：443-569-9228
- メール：arasmussen@renibus.com
研究場所
-
-
California
-
Chula Vista、California、アメリカ、91910
- 募集
- Study Site
-
Los Angeles、California、アメリカ、90022
- 募集
- Study Site
-
Sacramento、California、アメリカ、95817
- 募集
- Study Site
-
San Diego、California、アメリカ、92111
- 募集
- Study Site
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- Study Site
-
-
Delaware
-
Newark、Delaware、アメリカ、19713
- 募集
- Study Site
-
-
Florida
-
Edgewater、Florida、アメリカ、32132
- 募集
- Study Site
-
Margate、Florida、アメリカ、33063
- 募集
- Study Site
-
Miami Springs、Florida、アメリカ、33166
- 募集
- Study Site
-
Orlando、Florida、アメリカ、32806
- 募集
- Study Site
-
-
Georgia
-
Augusta、Georgia、アメリカ、30904
- 終了しました
- Study Site
-
-
Idaho
-
Boise、Idaho、アメリカ、83706
- 募集
- Study Site
-
Chubbuck、Idaho、アメリカ、83201
- 募集
- Study Site
-
Idaho Falls、Idaho、アメリカ、83401
- 募集
- Study Site
-
-
Illinois
-
Chicago、Illinois、アメリカ、60643
- 募集
- Study Site
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- 募集
- Study Site
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40205
- 募集
- Study Site
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112
- 募集
- Study Site
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- 募集
- Study Site
-
Pontiac、Michigan、アメリカ、48341
- 募集
- Study Site
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- 募集
- Study Site
-
-
New York
-
Fresh Meadows、New York、アメリカ、11365
- 募集
- Study Site
-
New York、New York、アメリカ、10016
- 募集
- Study Site
-
-
North Carolina
-
Winston-Salem、North Carolina、アメリカ、27103
- 募集
- Study Site
-
-
Texas
-
Fort Worth、Texas、アメリカ、76110
- 募集
- Study Site
-
Houston、Texas、アメリカ、77054
- 募集
- Study Site
-
San Antonio、Texas、アメリカ、78212
- 募集
- Study Site
-
Van Vleck、Texas、アメリカ、77482
- 募集
- Study Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Have provided written informed consent prior to participation in the study.
- Male or female participants 18 years of age or older.
- Diagnosed with CKD (eGFR < 60 mL/min/1.73m2) and not expected to require renal replacement therapy (dialysis or kidney transplant) throughout the duration of the study.
- Within 6 months prior to screening have at least two SBC between 12 and 20 mmol/L, inclusive. If only one historical SBC is available, a second SBC may be drawn on screening visit S1 and analyzed by the local laboratory.
- Within screening period have two central laboratory SBC (at least 24 hours apart and more than 4 hours after food) between 12 and 21 mmol/L, inclusive.
- Willing to keep food consumption similar to baseline throughout the entire study.
- If taking oral alkali therapy, dose has been stable for at least 28 days prior to the start of screening and is expected to remain stable throughout the study.
- Women who are of childbearing potential must have a negative pregnancy test and agree to abstinence or to use contraception.
Exclusion Criteria:
-
Any participant deemed by the Investigator to be an inappropriate candidate for PerfO testing (e.g., severe musculoskeletal pain, non-ambulatory status), inability to complete STS5 without support or with a screening STS5 time < 10 seconds.
-
History or current diagnosis of:
- Clinically significant gastroparesis or a history of bariatric surgery.
- Bowel obstruction, swallowing disorders, severe gastrointestinal disorders, including inflammatory bowel disease, major gastrointestinal surgery including gastrectomy, or known active gastric/duodenal ulcers.
- Severe recurrent diarrhea or constipation, as assessed by the Investigator.
- Pernicious anemia, atrophic or autoimmune gastritis, achlorhydria or hypochlorhydria.
-
Ineligible per REVIVE GastroScreen test.
-
Use of GI polymer binders or sodium zirconium cyclosilicate within 14 days prior to the start of screening or have an expectation to initiate treatment during the study.
-
Use of acid reducing drugs, including PPIs, H2RAs or P-CABs within 14 days prior to the start of screening or have an expectation to initiate treatment during the study. Very sporadic use (one time per week or less) may be acceptable, as assessed by the Investigator.
-
Initiation of GLP-1 receptor agonists within 6 months prior to the start of screening, or expectation to initiate use during the study. Participants that have been on a GLP-1 receptor agonist for more than 6 months and have maintained a stable dose and steady body weight for at least one month prior to the start of screening may be considered for enrollment, upon Medical Monitor review. GLP-1 receptor agonists also should not be started during the study.
-
Participants that are taking any of the following medications and have not been on a stable dose for at least 14 days prior to the start of screening or have an expectation to change dose during the study: diuretics, non-ophthalmic carbonic anhydrase inhibitors, diabetes drugs, RAAS inhibitors, calcium or magnesium supplements, non-polymer phosphate binders, and SGLT-2 inhibitors. These medications also should not be started during the study.
-
Active, recurrent, or metastatic malignancy at the start of screening.
-
History of malignancy, except under the following conditions:
- Carcinoma in situ (e.g., of the cervix, breast, or bladder) that has been completely excised and shows no evidence of residual disease.
- Non-melanoma skin cancers (e.g., basal cell carcinoma, squamous cell carcinoma) that have been completely excised and show no evidence of recurrence.
- Low grade prostate cancer, in the opinion of the Investigator (i.e., no metastasis, Gleason score < 6), with no significant worsening for > 6 months prior to the screening visit.
- Any other malignancy that was treated with curative intent and has been in complete remission for ≥ 5 years prior to the screening visit.
-
Two or more hospitalizations within 12 months prior to the start of screening or a hospitalization within the last 3 months prior to the start of screening due to fluid overload, heart failure, acute kidney injury (AKI) or electrolyte disorders, including hyperkalemia. Participants that have not been hospitalized within the past 3 months and whose condition is stable may be considered for enrollment.
-
Screening hemoglobin < 9 g/dL.
-
Low bicarbonate value(s) at time of screening that are due to underlying primary respiratory alkalosis.
-
Investigational medication administration within 28 days prior to start of screening.
-
Participants that are taking an average of > 30 units of insulin daily, unless recent (within last 6 months) hemoglobin A1C is < 6.5%.
-
History of alcoholism or drug/chemical abuse within 1 year prior to the start of screening, in the opinion of the Investigator.
-
Current, regular use of inhaled/ingested cannabis/THC products.
-
Inability to take the IP or otherwise comply with the protocol.
-
Any medical condition, uncontrolled systemic disease or serious concurrent illness that would significantly decrease study compliance or jeopardize the safety of the participant or affect the validity of the trial results, in the opinion of the Investigator.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター：プラセボ
|
Group 2: 9 g PBO BID |
|
実験的：Veverimer
|
Group 1: 9 g veverimer BID |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
血清重炭酸濃度（SBC）の変化を測定することによるVeverimerの有効性
時間枠：来院：スクリーニングから168日目まで
|
来院：スクリーニングから168日目まで
|
|
STS5（5回立ち座りテスト）により評価された身体的パフォーマンス改善におけるVeverimerの有効性。
時間枠：来院：スクリーニングから168日目まで
|
来院：スクリーニングから168日目まで
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].
時間枠：Visits: Screening to Day 168
|
Visits: Screening to Day 168
|
|
|
Efficacy of Veverimer in achieving SBC and responder thresholds.
時間枠：Visits: Screening to Day 168
|
Change from baseline in SBC. Achievement of SBC thresholds (> 4 mmol/L increase from baseline and/or > 23 mmol/L). |
Visits: Screening to Day 168
|
|
Performance outcomes (PerfO).
時間枠：Visits: Screening to Day 168
|
Change in Patient Global Impression of Change of Physical Functioning (PGI-C) Patients answer 1 question: How would you rate your current level of physical functioning (mobility and ability to do everyday physical activities) compared to the beginning of the study? Much better, Moderately better, A little better, No change, A little worse, Moderately worse, Much worse. Lower score is a better outcome. Change in Patient Global Impressions Scale - Severity (PGI-S) Patients answer 1 question: How would you rate your current level of physical functioning (mobility and ability to do everyday physical activities)? Poor, Fair, Good, Very good, Excellent. Higher score is a better outcome. |
Visits: Screening to Day 168
|
|
Frailty and muscle mass assessment.
時間枠：Visits: Screening to Day 168
|
Change in performance on 6-minute walk test 6MWT. |
Visits: Screening to Day 168
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。